on this page
Patient eligibility
The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with nusinersen, onasemnogene abeparvovec and risdiplam under the National Health Act 1953, section 100 for patients with SMA.
Where the term disease modifying therapy appears it refers to nusinersen and risdiplam. Where the term gene therapy appears it refers to onasemnogene abeparvovec.
Nusinersen and risdiplam are PBS-subsidised for both symptomatic and pre-symptomatic SMA.
Onasemnogene abeparvovec is PBS-subsidised gene therapy for both symptomatic Type 1 SMA and pre-symptomatic SMA for patients no older than 9 months of age. Treatment with onasemnogene abeparvovec is once only in a lifetime.
Patients must be eligible for the PBS and meet the relevant restriction criteria.
The Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing nusinersen, onasemnogene abeparvovec and risdiplam.
Section 100 arrangements
nusinersen, onasemnogene abeparvovec, and risdiplam
These items are only PBS-subsidised for non-admitted patients, day admitted patients, or patients on discharge who are attending:
- an approved private hospital (nusinersen and risdiplam only)
- a public hospital.
These items aren’t PBS-subsidised for public hospital in-patients. You must include the hospital name and provider number on the authority application form.
Treatment specifics
Nusinersen for patients aged 18 years or younger
To be eligible for PBS-subsidised treatment with nusinersen for initial treatment, patients must be treated by, or in consultation with, a specialist medical practitioner who is both:
- experienced in the diagnosis and management of SMA
- associated with a neuromuscular clinic of a recognised hospital in the management of SMA.
For continuing treatment, patients must either be treated by, or have their treatment initiated by, or in consultation with, a specialist medical practitioner who is both:
- experienced in the diagnosis and management of SMA
- associated with a neuromuscular clinic of a recognised hospital in the management of SMA.
Hospitals recognised for managing SMA are:
- Queensland Children’s Hospital - Brisbane
- Royal Children’s Hospital - Melbourne
- Monash Children’s Hospital - Melbourne
- John Hunter Hospital - Newcastle
- Sydney Children’s Hospital - Randwick
- Children’s Hospital at Westmead
- Adelaide Women and Children’s Hospital
- Perth Children’s Hospital.
Nusinersen for adult patients with onset of SMA prior to 19 years of age
To be eligible for PBS-subsidised treatment with nusinersen for initial and continuing treatment, patients must be treated by either:
- a specialist medical practitioner experienced in the diagnosis and management of SMA
- a medical practitioner directed to prescribe this benefit by a specialist medical practitioner experienced in the diagnosis and management of SMA.
Onasemnogene abeparvovec
To be eligible for PBS-subsidised treatment with onasemnogene abeparvovec, patients must be treated by, or in consultation with, a specialist medical practitioner who is both:
- experienced in the diagnosis and management of SMA
- associated with a neuromuscular clinic of a recognised hospital in the management of SMA.
Hospitals recognised for managing SMA are:
- Queensland Children’s Hospital - Brisbane
- Royal Children’s Hospital - Melbourne
- Monash Children’s Hospital - Melbourne
- John Hunter Hospital - Newcastle
- Sydney Children’s Hospital - Randwick
- Children’s Hospital at Westmead
- Adelaide Women and Children’s Hospital
- Perth Children’s Hospital.
Patients must be treated in a treatment centre that is each of the following:
- recognised in the management of SMA
- accredited in the use of this gene technology by the relevant authority
- has sourced or will source this product from an accredited supplier.
Accredited treatment centres and suppliers are those organisations accredited by the Gene Technology Regulator under section 92 of the Gene Technology Act 2000. The list of accredited organisations is available on the Department of Health and Aged Care website. These may be updated without notice.
Risdiplam for patients aged 18 years or younger
To be eligible for PBS-subsidised treatment with risdiplam for symptomatic Type I/II/IIIa SMA, patients must be treated by, or in consultation with, a specialist medical practitioner who is both:
- experienced in the diagnosis and management of SMA
- associated with a neuromuscular clinic.
To be eligible for PBS-subsidised treatment with risdiplam for symptomatic Type IIIB/IIIC SMA, patients must be treated by either:
- a specialist medical practitioner experienced in the diagnosis and management of SMA
- a medical practitioner directed to prescribe this benefit by a specialist medical practitioner experienced in the diagnosis and management of SMA.
To be eligible for PBS-subsidised treatment with risdiplam for pre-symptomatic SMA, patients must be treated by, or in consultation with, a specialist medical practitioner who is both:
- experienced in the diagnosis and management of SMA
- associated with a neuromuscular clinic of a recognised hospital in the management of SMA.
Hospitals recognised for managing SMA are:
- Queensland Children’s Hospital - Brisbane
- Royal Children’s Hospital - Melbourne
- Monash Children’s Hospital - Melbourne
- John Hunter Hospital - Newcastle
- Sydney Children’s Hospital - Randwick
- Children’s Hospital at Westmead
- Adelaide Women and Children’s Hospital
- Perth Children’s Hospital.
Risdiplam for adult patients with onset of SMA prior to 19 years of age
To be eligible for PBS-subsidised treatment with risdiplam for initial and continuing treatment, patients must be treated by either:
- a specialist medical practitioner experienced in the diagnosis and management of SMA
- a medical practitioner directed to prescribe this benefit by a specialist medical practitioner experienced in the diagnosis and management of SMA.
Authority applications
Disease modifying therapy
Patients 18 years of age or younger
Applying for initial treatment
Apply for initial authority approval to prescribe PBS-subsidised nusinersen or risdiplam to treat SMA in writing and either:
- use HPOS Form upload
- mail to PBS Complex Drugs Programs.
All written applications must include:
- details of the proposed prescription or prescriptions
- the completed spinal muscular atrophy paediatric - nusinersen or risdiplam - initial authority application form
- relevant attachments.
Applying for continuing or change of treatment
Applications to continue or change authority approval to prescribe PBS-subsidised nusinersen or risdiplam to treat SMA can be made either:
- in real time using the Online PBS Authorities system
- by calling the PBS Complex Drug Programs enquiry line.
For risdiplam applications, you must request the quantity of the drug and number of repeats in accordance with the recommended dosing in the approved Product Information. The quantity can’t exceed 3 units.
Patients 19 years of age or older
Applying for initial treatment
Apply for initial authority approval to prescribe PBS-subsidised nusinersen or risdiplam for adult patients who didn’t initiate PBS subsidy during childhood to treat SMA in writing and either:
- use HPOS Form upload
- mail to PBS Complex Drugs Programs.
All written applications must include:
- details of the proposed prescription or prescriptions
- the completed spinal muscular atrophy adult - nusinersen or risdiplam - initial authority application form
- relevant attachments.
Applying for continuing or change of treatment
Applications to continue or change authority approval to prescribe PBS-subsidised nusinersen or risdiplam to treat SMA can be made either:
- in real time using the Online PBS Authorities system
- by calling the PBS Complex Drug Programs enquiry line.
Gene therapy
Apply for authority approval to prescribe PBS-subsidised onasemnogene abeparvovec to treat SMA in writing and either:
- use HPOS Form upload
- mail to PBS Complex Drugs Programs.
All written applications must include:
- details of the proposed prescription or prescriptions
- the completed spinal muscular atrophy - onasemnogene abeparvovec - authority application form
- relevant attachments.
You must state the patient’s weight in kilograms and request the appropriate product pack presentation with respect to the mix of 5.5 mL and 8.3 mL vials.
More information
Call the PBS Complex Drugs Programs enquiry line for more information.